Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone ...

Phase 3 ROADS enrolled 204 patients across 32 centers (2021–2025) with 2–7 cm brain metastases, comparing tile-based intraoperative radiation versus external stereotactic radiation. Surgical bed ...

For-profit companies now dominate hospice care in the U.S., and private equity firms are moving in. Some say the trend reflects the underlying economics and need for scale. Like all things in ...

In this final interview of a three-part video series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, told MHE, in response to our recent annual Pharmacy Survey results, ...

GLP-1 medications, especially for diabetes, will remain an influential cost driver in drug spending this year, supported by broader prescriber adoption and patient demand. Spending on non-specialty ...

Initial Medicare Part D drug price negotiations may not yield expected savings, with payers likely increasing utilization management to manage costs. CMS-negotiated discounts are similar to private ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are mixed. tt was supposed to be the start of a new era of ...

FDA Priority Review for finerenone in T1D with CKD could establish the first non-steroidal MRA option in this population, addressing substantial residual renal and CV risk. Mineralocorticoid receptor ...

Per-capita medical costs increased 7.9% to $8,460 in 2026, while a modeled family of four reached $37,824 under employer-sponsored coverage. Outpatient facility spend grew 7.5% to ~31% of total costs, ...

Accelerated approval was supported by MYR301 using HDV RNA reduction and ALT normalization as endpoints across treatment up to 144 weeks with 96 weeks off-treatment follow-up. Virologic responses ...

A 36-hour pre-chemotherapy plus 24-hour post-chemotherapy fasting protocol (≤350 kcal/day, liberal water/herbal tea, limited vegetable juice) was feasible and reportedly well tolerated in HGSOC.

In ‘A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends,’ the expert dermatologist examined the following critical questions: In ‘A Milestone in Vitiligo: Clinical Efficacy ...